Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive De-escalation of Radiation Therapy Dose in HPV-Positive Oropharyngeal Carcinoma (ART)
NCT03215719Phase 2Recruiting
- Sponsor
- NYU Langone Health
- Start
- Oct 2017
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cisplatin in oropharyngeal squamous cell carcinoma (OPSCC), sponsored by NYU Langone Health. Started Oct 2017; status: recruiting.
02
Drugs
cisplatin
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT03215719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03215719.